BARRIER THERAPEUTICS INC 4
Accession 0000950142-04-001468
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 3:51 PM ET
Size
26.1 KB
Accession
0000950142-04-001468
Insider Transaction Report
- Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying)
- Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying)
- Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total
- Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying)
- Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying)
- Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying)
- Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying)
- Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total
- Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying)
- Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total - Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying)
Footnotes (3)
- [F1]On April 28, 2004, each share of the Issuer's Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into 0.5 shares of Common Stock. This gives effect to the 1-for-2 reverse stock split that occurred on April 28, 2004.
- [F2]All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, L.P. ("Perseus-Soros"). Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"), is the general partner of Perseus-Soros. Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners"), and SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), are the managing members of Perseus-Soros Partners. Perseus EC, L.L.C., a Delaware limited liability company ("Perseus EC"), is the managing member of Perseus Partners. Perseuspur, LLC, a Delaware limited liability company ("Perseuspur"), is a member of Perseus EC. Mr. Frank H. Pearl ("Mr. Pearl") is the sole member of Perseuspur.
- [F3]SFM AH LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC"). Mr. George Soros serves as Chairman of SFM LLC.
Documents
Issuer
BARRIER THERAPEUTICS INC
CIK 0001173657
Related Parties
1- filerCIK 0001173657
Filing Metadata
- Form type
- 4
- Filed
- Apr 29, 8:00 PM ET
- Accepted
- Apr 30, 3:51 PM ET
- Size
- 26.1 KB